Changes in biomarkers after 180 days of tobacco heating product use: a randomised trial.
Biomarkers of exposure
Biomarkers of potential harm
Cigarette smoking
Modified risk tobacco product
Tobacco heating product
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
09
04
2021
accepted:
15
06
2021
pubmed:
2
7
2021
medline:
30
11
2021
entrez:
1
7
2021
Statut:
ppublish
Résumé
The aim of this study was to investigate whether biomarkers of exposure (BoE) and potential harm (BoPH) are modified when smokers switch from smoking cigarettes to exclusive use of a tobacco heating product (THP) in an ambulatory setting. Participants in this randomised, controlled study were healthy volunteer smokers assigned either to continue smoking or switch to a THP, and a control group of smokers who abstained from cigarette smoking. Various BoE and BoPH related to oxidative stress, cardiovascular and respiratory diseases, and cancer were assessed at baseline and up to 180 days. In continuing smokers, BoE and BoPH remained stable between baseline and day 180, while THP users' levels of most BoE reduced significantly, becoming similar to those in controls abstaining from cigarette smoking. Also at 180 days, significant changes in numerous BoPH, including total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, 8-epi-prostaglandin F2α type III, fractional concentration of exhaled nitric oxide and white blood cell count, were directionally consistent with lessened health impact. Our findings support the notion that the deleterious health impacts of cigarette smoking may be reduced in smokers who completely switch to using THPs.
Identifiants
pubmed: 34196886
doi: 10.1007/s11739-021-02798-6
pii: 10.1007/s11739-021-02798-6
pmc: PMC8563516
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2201-2212Informations de copyright
© 2021. The Author(s).
Références
N Engl J Med. 1995 May 4;332(18):1198-203
pubmed: 7700313
Cancer Res. 2014 Jan 15;74(2):401-11
pubmed: 24408916
Biomarkers. 2013 Sep;18(6):467-86
pubmed: 23902266
Nicotine Tob Res. 2019 Jan 1;21(1):3-13
pubmed: 29253243
Regul Toxicol Pharmacol. 2018 Mar;93:14-33
pubmed: 29080848
Tob Control. 2001 Jun;10(2):189-95
pubmed: 11387543
Regul Toxicol Pharmacol. 2015 Jul;72(2):273-91
pubmed: 25957570
BMJ. 1994 Oct 8;309(6959):901-11
pubmed: 7755693
Nicotine Tob Res. 2020 Apr 17;22(4):549-559
pubmed: 31125079
Nicotine Tob Res. 2020 Apr 17;22(4):539-548
pubmed: 30722062
Nicotine Tob Res. 2021 Feb 16;23(3):584-591
pubmed: 32776101
Regul Toxicol Pharmacol. 2018 Mar;93:4-13
pubmed: 29080851
Nicotine Tob Res. 2018 Sep 4;20(10):1237-1242
pubmed: 29059444
Intern Emerg Med. 2019 Sep;14(6):885-898
pubmed: 31049783
Cancers (Basel). 2014 May 14;6(2):1138-56
pubmed: 24830349
Inhal Toxicol. 2011 Feb;23(3):148-56
pubmed: 21391783
Nicotine Tob Res. 2006 Apr;8(2):169-91
pubmed: 16766411
Nicotine Tob Res. 2019 Aug 19;21(9):1220-1227
pubmed: 29912406
Nicotine Tob Res. 2012 Jan;14(1):75-8
pubmed: 22025545
Nicotine Tob Res. 2018 Jan 5;20(2):173-182
pubmed: 28177498
Contemp Clin Trials Commun. 2020 Jan 28;17:100535
pubmed: 32072070
Int J Mol Sci. 2020 Aug 27;21(17):
pubmed: 32867116
Int J Cancer. 2012 Mar 15;130(6):1338-46
pubmed: 21544809
MMWR Morb Mortal Wkly Rep. 2017 Jan 06;65(52):1457-1464
pubmed: 28056007
J Am Coll Cardiol. 2004 Nov 16;44(10):1945-56
pubmed: 15542275
Drug Alcohol Depend. 2015 Sep 1;154:184-91
pubmed: 26205313
Biometrics. 1979 Sep;35(3):549-56
pubmed: 497341
Free Radic Res. 2009 Jan;43(1):85-91
pubmed: 19085196
Regul Toxicol Pharmacol. 2018 Apr;94:203-233
pubmed: 29428304
Atherosclerosis. 2020 Jun;302:36-42
pubmed: 32438197
Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1934-1943
pubmed: 31270101